New York, NY – For decades, the role of regulatory T (Treg) cells in cancer has presented a perplexing paradox. These powerful immune suppressors, designed to maintain the body’s delicate immune balance, are typically associated with worse outcomes in most solid tumors, acting as formidable "brakes" that impede the immune system’s crucial ability to attack malignant cells. Yet, colorectal cancer has consistently defied this understanding, standing out as a confounding exception where a higher presence of Treg cells has inexplicably correlated with longer patient survival. This long-standing mystery has baffled oncologists and immunologists alike, hindering the development of effective, broadly applicable immunotherapies for this deadly disease.
Now, a groundbreaking study from researchers at the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering Cancer Center (MSK) has finally offered a clear, compelling explanation for this anomaly. Published in the esteemed scientific journal Immunity, the findings reveal that not all Treg cells are created equal. Instead, the key lies in the type of Treg cell present, rather than merely their quantity, fundamentally reshaping our understanding of immune responses within the tumor microenvironment. This pivotal discovery promises to significantly improve immunotherapy strategies for the vast majority of colorectal cancer patients and potentially extend to other cancers arising in "barrier tissues" like the skin, stomach lining, mouth, and throat.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explains Alexander Rudensky, PhD, co-senior author of the study and Chair of the Immunology Program at MSK. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches in therapeutic interventions."
A Decades-Long Scientific Journey Culminates in Breakthrough
This landmark study is the culmination of more than two decades of dedicated research by Dr. Rudensky, recognized globally as one of the foremost authorities on regulatory T cells. His pioneering work has been instrumental in establishing the critical function of Treg cells in maintaining "immune tolerance." This vital process allows the immune system to accurately differentiate between harmful pathogens and benign entities, preventing autoimmune reactions against the body’s own cells, beneficial microbes, and everyday environmental exposures like food. Over the years, Dr. Rudensky’s laboratory has meticulously uncovered the intricate mechanisms governing Treg cell development, function, and their profound influence on various disease pathologies, including cancer progression.
The current research was spearheaded by a collaborative team of first authors: Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now affiliated with the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, who also served as the study’s other senior author. Their collective expertise in immunology, oncology, and computational biology proved critical in dissecting the complex data that ultimately illuminated the dual nature of Treg cells in colorectal cancer.
Focusing on the Most Prevalent Form of Colorectal Cancer
Colorectal cancer remains a formidable public health challenge. According to the American Cancer Society, it ranks as the second leading cause of cancer-related death when statistics for men and women are combined. The MSK study specifically focused on the most common manifestation of the disease, which accounts for an estimated 80% to 85% of all colorectal cancer cases. These tumors are characterized as microsatellite stable (MSS) with proficient mismatch repair (MMRp), meaning their DNA exhibits relative stability. Unfortunately, this predominant subgroup of colorectal cancers typically responds poorly to current checkpoint inhibitor immunotherapies, leaving patients with limited treatment options and a pressing need for novel therapeutic strategies.
This contrasts sharply with earlier research at MSK and elsewhere, which demonstrated the remarkable efficacy of checkpoint inhibitors against a different tumor type: cancers exhibiting high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd). For these patients, immunotherapy alone has often proven highly effective, frequently allowing them to circumvent aggressive treatments such as surgery, chemotherapy, and radiation. The lack of response in MSS/MMRp colorectal cancer has long been a significant clinical hurdle, underscoring the importance of the current study’s findings in identifying a new avenue for intervention.
The Dual Nature of Treg Cells: Opposing Effects Unveiled
To unravel the unique immunological landscape of common colorectal cancers, the research team employed a sophisticated mouse model developed at MSK. This model meticulously mimics the genetic alterations, pathological behavior, and immune microenvironment characteristic of human colorectal tumors, providing an invaluable platform for mechanistic investigations.
Through a series of meticulously designed experiments, the researchers made a pivotal discovery: tumor-associated Treg cells are not a monolithic population but rather comprise two distinct main groups. One group actively produces a crucial signaling molecule, or cytokine, known as interleukin-10 (IL-10). The other group, notably, does not.
By selectively ablating each of these Treg cell groups in a controlled manner, the scientists uncovered starkly contrasting effects on tumor growth:
-
The Beneficial Brakes (IL-10-positive Treg cells): These Treg cells were found to actively slow tumor progression. Their mechanism of action involves reducing the activity of Th17 cells, another type of immune cell that secretes interleukin-17 (IL-17). IL-17 is known to act as a potent growth signal for tumors, promoting their proliferation and survival. By dampening Th17 cell activity and subsequent IL-17 production, IL-10-positive Treg cells effectively exert a protective, anti-tumor effect. Intriguingly, these beneficial Treg cells were predominantly found in the healthy tissue surrounding the tumor rather than deep within the malignant mass. When these IL-10-positive Treg cells were experimentally removed, tumors exhibited significantly accelerated growth, underscoring their critical protective role.
-
The Harmful Accelerators (IL-10-negative Treg cells): In stark contrast, the IL-10-negative Treg cells exerted the opposite effect, actively promoting tumor growth. These cells were found to suppress the activity of powerful immune defenders, most notably CD8+ T cells, which are widely recognized for their direct cancer-fighting capabilities. By inhibiting CD8+ T cells, these harmful Treg cells create an immunosuppressive environment that allows cancer cells to evade immune surveillance and thrive. This detrimental subtype was primarily localized within the tumor itself, strategically positioned to neutralize anti-tumor immune responses. When IL-10-negative Treg cells were selectively eliminated, tumors demonstrated a significant reduction in size, highlighting their role as key drivers of immune evasion and tumor progression.
Patient Data Confirms the Findings: A Clinical Validation
The robustness of these preclinical findings was critically validated through the analysis of tumor samples obtained from human colorectal cancer patients. The team successfully identified the same two distinct populations of IL-10-positive and IL-10-negative Treg cells within these human samples, confirming the translational relevance of their mouse model observations.
Further strengthening their conclusions, the researchers analyzed clinical outcomes for over 100 colorectal cancer patients. The results were compelling: patients whose tumors contained higher levels of the beneficial IL-10-positive Treg cells exhibited significantly longer survival. Conversely, patients whose tumors harbored a greater proportion of the harmful IL-10-negative Treg cells experienced poorer clinical outcomes, unequivocally linking the presence and balance of these distinct Treg subtypes to patient prognosis.
"This research shows how important these positive cells are," affirms Dr. Huang. "And it highlights the urgent need to develop therapies that can selectively eliminate the harmful Tregs while carefully preserving the helpful ones, thereby rebalancing the immune response within the tumor."
Targeting CCR8: A Promising New Therapeutic Frontier
The profound implications of these findings extend directly to the development of novel therapeutic strategies, particularly for the majority of colorectal cancer patients who currently lack effective immunotherapy options. Dr. Rudensky, who is also a Howard Hughes Medical Institute Investigator, points to a clear path forward.
The researchers discovered a critical distinguishing marker: the harmful IL-10-negative Treg cells express exceptionally high levels of a protein known as CCR8. Crucially, these are the cells responsible for suppressing the immune response and are predominantly concentrated within the tumor microenvironment. This differential expression of CCR8 offers a highly specific target for therapeutic intervention.
This insight builds upon earlier pioneering work from Dr. Rudensky’s lab, notably led by breast cancer surgeon George Plitas, MD. That research demonstrated that CCR8 is also highly expressed on tumor-associated Treg cells in breast cancer and numerous other human malignancies. This prior work laid the foundation for the concept that antibodies could be engineered to selectively deplete these harmful CCR8-expressing Treg cells. Such an approach could liberate the immune system to mount a more effective attack against tumors, all while leaving the beneficial, non-CCR8-expressing Treg cells intact and functional.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is now the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky emphasizes. Indeed, multiple clinical trials are currently underway at MSK and other leading institutions worldwide, evaluating this innovative approach both as a standalone therapy and in combination with existing immunotherapies. The new study provides robust preclinical and clinical evidence, significantly strengthening the rationale for deploying this strategy not only in colorectal cancer but potentially across a broader spectrum of malignancies.
Broader Horizons: Similar Immune Patterns in Other Cancers
The research team further explored the potential generalizability of their findings by analyzing a vast dataset of T cells derived from 16 different cancer types. Their comprehensive analysis revealed that similar divisions between IL-10-positive and IL-10-negative Treg cells, with their respective opposing roles, appeared in several other cancers. These included malignancies affecting the skin and the lining of the mouth, throat, and stomach – tissues collectively referred to as "barrier tissues."
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," notes Dr. Mitra, who led the intricate data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. This commonality suggests a shared immunological landscape where distinct Treg subsets may perform tissue-specific functions. The implication is profound: therapies designed to remove IL-10-negative Treg cells in colorectal cancer might also prove effective against these other cancers that arise in analogous barrier tissues, opening up exciting new avenues for treatment beyond the gastrointestinal tract.
Metastatic Disease: A Different Immunological Landscape
While the findings offer immense promise for primary colorectal tumors, the researchers also delved into the immunological characteristics of metastatic disease. When they investigated colorectal cancer that had spread to the liver, they observed a notably different immune pattern.
In these metastatic tumors, the harmful IL-10-negative Treg cells significantly outnumbered their beneficial IL-10-positive counterparts. This shift in balance profoundly altered the therapeutic implications. Unlike primary tumors where selective targeting is crucial, the removal of all Treg cells in this metastatic context resulted in tumor shrinkage. This observation underscores a critical principle: treatment strategies must be meticulously tailored not only to the specific tissue involved but also to the stage of the disease, recognizing the dynamic evolution of the tumor microenvironment as cancer progresses and metastasizes.
Looking Ahead: A New Era of Immunotherapy
The study by the MSK team marks a paradigm shift in our understanding of regulatory T cells in cancer. By dissecting the once-mysterious role of Treg cells in colorectal cancer, these researchers have moved beyond simple cell counts to reveal the intricate functional diversity within these immune populations. The discovery of distinct, opposing Treg subtypes – one beneficial, one harmful – offers a precise target for therapeutic intervention, particularly for the vast majority of colorectal cancer patients who currently lack effective immunotherapy options.
The identification of CCR8 as a marker for the harmful Treg subset, coupled with ongoing clinical trials of CCR8-depleting antibodies, represents a tangible and immediate step towards translating this scientific breakthrough into tangible patient benefit. Furthermore, the potential applicability of these findings to other barrier tissue cancers suggests a broader impact, offering hope for a new generation of immunotherapies that are more selective, more effective, and ultimately, more personalized. This research not only solves a decades-long enigma but also illuminates a promising path forward in the relentless fight against cancer, ushering in an era where the immune system can be precisely re-engineered to unleash its full potential against malignant cells.
Authors, Funding, and Disclosures:
Additional authors contributing to this significant work include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
Key institutional support was provided by the Integrated Genomics Operation and the Single Cell Research Initiative at MSK, whose advanced facilities were instrumental in the execution of the research.
Funding for this study was generously provided by the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
Dr. Rudensky maintains various professional affiliations and holds equity in several biotechnology and pharmaceutical companies, including Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He also serves as a scientific advisory board member for Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and holds editorial roles for the Journal of Experimental Medicine and Immunity.
Importantly, Dr. Rudensky and Dr. Plitas are inventors on patents and patent applications held by MSK, specifically related to CCR8-based therapeutic depletion of tumoral Treg cells and the development of novel antibodies targeting CCR8, underscoring the direct translational potential of their research.
About the Author
